Cambridge, UK - 25 September 2018- Acacia Pharma Group plc (the "Company") (Euronext: ACPH) is pleased to announce that both resolutions as set out in the Notice of General Meeting dated 7 September 2018 were duly passed by the required majority at the General Meeting held earlier today.
The results of the votes on the resolutions are shown in the table below and will be posted on the Company's website at www.acaciapharma.com.
| Resolution | Votes for1 | %of vote | Votes against | %of vote | Total votes for and against | % of issued share capital voted | |
| 1 | Allot ordinary shares up to an aggregate nominal amount of £531,190.61 | 31,681,052 | 99.36 | 205,443 | 0.64 | 31,886,495 | 60.00 |
| 2 | Disapply statutory pre- emption rights up to an aggregate nominal amount of £531,190.612 | 31,681,052 | 99.36 | 205,443 | 0.64 | 31,886,495 | 60.00 |
- Where shareholders appointed the Chairman or another Director as their proxy with discretion as to voting, their votes were cast in favour of the resolutions and their shares have been included in the "votes for" column
- Indicates Special Resolution
As at 6.30 p.m. on 21 September 2018 (being the time at which shareholders who wanted to attend and vote at the meeting were required to have their details entered in the register of members) there were 53,119,061 shares of 2p each in issue.
A copy of the resolution passed as special business at the General Meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM.
Contacts
| Acacia Pharma Group plc Julian Gilbert, CEO Christine Soden, CFO IR@acaciapharma.com | +44 1223 919760 |
| Citigate Dewe Rogerson Mark Swallow, Shabnam Bashir, David Dible acaciapharma@citigatedewerogerson.com | +44 20 7638 9571 |
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Company has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Company's lead product, BARHEMSYSTM for post-operative nausea & vomiting (PONV), has generated positive results in Phase 3 clinical studies and an NDA is currently under review by the US FDA with a PDUFA goal date of 5 October 2018. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV), has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com
-Ends-